Grant Pickering Sells 15,000 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) Stock

Vaxcyte, Inc. (NASDAQ:PCVX) CEO Grant Pickering sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, March 25th. The shares were sold at an average price of $66.93, for a total transaction of $1,003,950.00. Following the transaction, the chief executive officer now directly owns 477,847 shares in the company, valued at approximately $31,982,299.71. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Grant Pickering also recently made the following trade(s):

• On Friday, March 1st, Grant Pickering sold 2,616 shares of Vaxcyte stock. The stock was sold at an average price of $73.70, for a total transaction of $192,799.20.
• On Thursday, February 1st, Grant Pickering sold 2,616 shares of Vaxcyte stock. The shares were sold at an average price of $73.91, for a total transaction of $193,348.56.
• On Monday, January 29th, Grant Pickering sold 30,000 shares of Vaxcyte stock. The stock was sold at an average price of $66.03, for a total transaction of $1,980,900.00.
• On Tuesday, January 23rd, Grant Pickering sold 15,000 shares of Vaxcyte stock. The stock was sold at an average price of $63.92, for a total value of $958,800.00.
• On Tuesday, January 2nd, Grant Pickering sold 2,616 shares of Vaxcyte stock. The shares were sold at an average price of $63.89, for a total value of $167,136.24.

Vaxcyte Stock Performance

Shares of NASDAQ PCVX opened at $68.31 on Friday. The firm has a 50 day moving average price of $71.21 and a 200 day moving average price of $59.55. The stock has a market cap of $7.41 billion, a P/E ratio of -16.54 and a beta of 0.91. Vaxcyte, Inc. has a 52-week low of $34.11 and a 52-week high of $82.04.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings results on Tuesday, February 27th. The company reported ($1.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by ($0.93). During the same quarter in the prior year, the business earned ($0.73) EPS. Analysts predict that Vaxcyte, Inc. will post -4.18 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PCVX. Parallel Advisors LLC lifted its stake in Vaxcyte by 155.3% in the fourth quarter. Parallel Advisors LLC now owns 411 shares of the company’s stock valued at $26,000 after buying an additional 250 shares in the last quarter. Russell Investments Group Ltd. acquired a new stake in shares of Vaxcyte during the first quarter worth $30,000. KBC Group NV bought a new stake in Vaxcyte in the 4th quarter valued at $97,000. Avior Wealth Management LLC acquired a new position in Vaxcyte in the 3rd quarter worth $178,000. Finally, Wells Fargo & Company MN increased its holdings in Vaxcyte by 162.5% during the 4th quarter. Wells Fargo & Company MN now owns 3,961 shares of the company’s stock worth $190,000 after purchasing an additional 2,452 shares in the last quarter. 96.78% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vaxcyte in a research report on Friday, January 12th. Bank of America upped their price objective on shares of Vaxcyte from $67.00 to $80.00 and gave the stock a “buy” rating in a report on Tuesday, January 2nd. Mizuho started coverage on shares of Vaxcyte in a report on Thursday, December 7th. They issued a “buy” rating and a $69.00 target price on the stock. Finally, Needham & Company LLC raised their price objective on shares of Vaxcyte from $73.00 to $95.00 and gave the stock a “buy” rating in a research note on Wednesday, February 28th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $78.50.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.